Gilead Sciences Inc. (GILD)

62.51
NASDAQ : Health Technology
Prev Close 64.22
Day Low/High 62.19 / 64.67
52 Wk Low/High 60.32 / 79.61
Avg Volume 5.98M
Exchange NASDAQ
Shares Outstanding 1.27B
Market Cap 81.33B
EPS 4.20
P/E Ratio 9.01
Div & Yield 2.52 (3.74%)

Latest News

China National Medical Products Administration Approves Biktarvy® (Bictegravir, Emtricitabine And Tenofovir Alafenamide) For Treatment Of HIV-1 Infection

China National Medical Products Administration Approves Biktarvy® (Bictegravir, Emtricitabine And Tenofovir Alafenamide) For Treatment Of HIV-1 Infection

Gilead Sciences, Inc. (NASDAQ: GILD) announced today that the China National Medical Products Administration (NMPA) has approved Biktarvy ® (bictegravir 50mg/emtricitabine 200mg/tenofovir alafenamide 25mg, BIC/FTC/TAF), a once-daily single tablet regimen...

Gilead Sciences Statement On U.S. Food And Drug Administration Advisory Committee's Recommendation On Descovy For PrEP™

Gilead Sciences Statement On U.S. Food And Drug Administration Advisory Committee's Recommendation On Descovy For PrEP™

Gilead Sciences, Inc. (NASDAQ: GILD) announced today that the Antimicrobial Drugs Advisory Committee (AMDAC) of the U.

(Photo: Business Wire)

(Photo: Business Wire)

Gilead Sciences Canada, Inc. (Gilead Canada) today announced that effective July 31, the Ontario Drug Benefit Program will provide eligible patients with access to Biktarvy ® (bictegravir 50 mg/emtricitabine 200 mg/tenofovir alafenamide 25 mg) tablets, a...

Gilead Sciences Announces Third Quarter 2019 Dividend

Gilead Sciences Announces Third Quarter 2019 Dividend

Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the company's Board of Directors has declared a cash dividend of $0.

Gilead Sciences Announces Second Quarter 2019 Financial Results

Gilead Sciences Announces Second Quarter 2019 Financial Results

Gilead Sciences, Inc. (Nasdaq: GILD) announced today its results of operations for the second quarter ended June 30, 2019.

Biggest Earnings Tuesday: Apple, Procter & Gamble, Under Armour and More

Biggest Earnings Tuesday: Apple, Procter & Gamble, Under Armour and More

Brace yourself. It's a busy earnings day! Here's list of key companies to watch for on Tuesday, July 30, 2019.

3 Trends Driving This Earnings Season

3 Trends Driving This Earnings Season

With a third of S&P 500 stocks having reported, these 3 trends are coming to the fore.

Small Caps Stage Comeback

But we’ve seen it before: They spike only to fall back down.

Gilead Announces Latest Data In Ongoing HIV Cure Research Program

Gilead Announces Latest Data In Ongoing HIV Cure Research Program

Gilead Sciences, Inc. (NASDAQ: GILD) today presented results from two studies of investigational toll-like receptor 7 (TLR7) agonists as part of an HIV cure research program.

Gilead Presents New Findings On Profile Of Descovy® For Potential Use As HIV Pre-exposure Prophylaxis Compared With Truvada®

Gilead Presents New Findings On Profile Of Descovy® For Potential Use As HIV Pre-exposure Prophylaxis Compared With Truvada®

Gilead Sciences, Inc. (NASDAQ: GILD) today presented additional results from the DISCOVER trial evaluating an investigational use of Descovy (emtricitabine 200 mg and tenofovir alafenamide 25 mg tablets; F/TAF) for HIV pre-exposure prophylaxis (PrEP).

One Prescription for Uncertain Market? Gilead Sciences

One Prescription for Uncertain Market? Gilead Sciences

Use buy-write orders as a conservative way to invest in GILD in these uneasy times.

Gilead Presents New Data On Biktarvy® For The Treatment Of HIV In Women And In Virologically Suppressed Patients With Known Resistance

Gilead Presents New Data On Biktarvy® For The Treatment Of HIV In Women And In Virologically Suppressed Patients With Known Resistance

Gilead Sciences, Inc. (NASDAQ: GILD) today presented findings from two Phase 3 trials - a trial demonstrating the effectiveness of switching to Biktarvy (bictegravir 50mg/emtricitabine 200mg/tenofovir alafenamide 25mg tablets, B/F/TAF) in women, and a...

Gilead Presents Proof-of-Concept Data For GS-6207, A First-in-Class Capsid Inhibitor, In People Living With HIV

Gilead Presents Proof-of-Concept Data For GS-6207, A First-in-Class Capsid Inhibitor, In People Living With HIV

Gilead Sciences, Inc. (NASDAQ: GILD) today presented the first clinical data in people living with HIV on GS-6207, an investigational, novel, selective, first-in-class inhibitor of HIV capsid function.

Gilead Sciences Licenses Respiratory And Herpes Antiviral Research Programs From Novartis

Gilead Sciences Licenses Respiratory And Herpes Antiviral Research Programs From Novartis

Gilead Sciences, Inc. (NASDAQ: GILD) announced today that it has licensed three preclinical antiviral programs from Novartis, including investigational agents with the potential to treat human rhinovirus, influenza and herpes viruses.

Gilead To Present New Data On HIV Prevention, Treatment And Cure Research At IAS 2019

Gilead To Present New Data On HIV Prevention, Treatment And Cure Research At IAS 2019

Gilead Sciences, Inc. (NASDAQ: GILD) today announced that new data from the company's HIV research and development programs will be presented at the 10 th International AIDS Society Conference on HIV Science (IAS 2019) being held in Mexico City from July...

Gilead Sciences Announces Changes To Senior Leadership Team

Gilead Sciences Announces Changes To Senior Leadership Team

Gilead Sciences, Inc. (Nasdaq: GILD) announced today changes to the company's senior leadership team.

Gilead Sciences' Chief Scientific Officer John McHutchison To Leave The Company

Gilead Sciences' Chief Scientific Officer John McHutchison To Leave The Company

Gilead Sciences, Inc. (Nasdaq: GILD) announced today that John McHutchison, AO, MD, Chief Scientific Officer and Head of Research & Development, has decided to leave the company, effective next month.

Gilead Sciences To Release Second Quarter 2019 Financial Results On Tuesday, July 30, 2019

Gilead Sciences To Release Second Quarter 2019 Financial Results On Tuesday, July 30, 2019

Gilead Sciences, Inc. (Nasdaq: GILD) announced today that its second quarter 2019 financial results will be released on Tuesday, July 30, after the market closes.

Kite Announces Plans To Bolster Industry-Leading Cell Therapy Manufacturing Capabilities With New Viral Vector Facility

Kite Announces Plans To Bolster Industry-Leading Cell Therapy Manufacturing Capabilities With New Viral Vector Facility

Kite, a Gilead Company (Nasdaq: GILD), today announced plans for a new 67,000-square-foot facility in Oceanside, California, dedicated to the development and manufacturing of viral vectors, a critical starting material in the production of cell therapies.

Will Gilead Sciences Stock Really Rally 33% From Here?

Will Gilead Sciences Stock Really Rally 33% From Here?

Shares of Gilead Sciences are jumping higher on its increased investment in Galapagos and a new outperform rating from Wells Fargo.

Gilead Boosts Investment in Inflammatory Specialist Galapagos by $5.1 Billion

Gilead Boosts Investment in Inflammatory Specialist Galapagos by $5.1 Billion

Gilead Sciences said Monday that it will boost its stake in Belgian listed biotech Galapagos NV by more than $5 billion in a "transformative" deal that could tap new opportunities for the California-based group in fibrosis and arthritis.

I'm Looking at Gilead and Merck for Buy Entry Positions

I'm Looking at Gilead and Merck for Buy Entry Positions

Let's see if either of these names provide an entry this week.

Gilead And Galapagos Enter Into Transformative Research And Development Collaboration

Gilead And Galapagos Enter Into Transformative Research And Development Collaboration

Gilead Sciences, Inc. (NASDAQ: GILD) and Galapagos NV (Euronext & NASDAQ: GLPG) today announced that they have entered into a 10-year global research and development collaboration.

Active vs. Passive Investing: What's the Difference?

Active vs. Passive Investing: What's the Difference?

Some investors like to buy and hold, others choose to be hands-on—buying, selling and capitalizing on short-term profits.

Gilead Appoints Christi L. Shaw As Chief Executive Officer Of Kite

Gilead Appoints Christi L. Shaw As Chief Executive Officer Of Kite

Gilead Sciences, Inc. (NASDAQ: GILD) today announced that Christi L.

Gilead Sciences And Renown Institute For Health Innovation Announce Strategic Collaboration To Advance Understanding Of Nonalcoholic Steatohepatitis (NASH)

Gilead Sciences And Renown Institute For Health Innovation Announce Strategic Collaboration To Advance Understanding Of Nonalcoholic Steatohepatitis (NASH)

Gilead Sciences, Inc. (Nasdaq: GILD) and the Renown Institute for Health Innovation (IHI) today announced a strategic collaboration to collect and analyze genetic and electronic health data that can enhance the understanding of nonalcoholic...

Buyout Speculation Picks Up in Biotech

Buyout Speculation Picks Up in Biotech

Here's my take on the M&A landscape as well as my own speculation of some possible logical buyout targets.

Gilead Announces Intent To Submit New Drug Application For Filgotinib To U.S. Food And Drug Administration This Year

Gilead Announces Intent To Submit New Drug Application For Filgotinib To U.S. Food And Drug Administration This Year

Gilead Sciences, Inc. (NASDAQ: GILD) today announced that at a recent pre-New Drug Application (NDA) meeting with the U.

TheStreet Quant Rating: C (Hold)